Truist Securities Maintains Buy on CVS Health, Raises Price Target to $102

Benzinga Newsdesk www.benzinga.com Positive 74.5%

Neg 0% Neu 0% Pos 74.5%

Truist Securities analyst David Macdonald maintains CVS Health (NYSE:CVS) with a Buy and raises the price target from $98 to $102.